Skip to main content

Table 1 KU-174 Activity Across NCI-60 Human Tumor Cell Lines

From: Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells

Leukemia Renal Cancer Melanoma Colon Cancer
CCRF-CEM 0.63 786-0 73.59 LOX-IMVI 9.59 COLO-205 0.63
HL-60(TB) 0.44 A498 83.68 MALME-3M 41.99 HCC-2998 42.97
K-562 23.12 ACHN 47.1 M14 -21.95 HCT-116 21.97
MOLT-4 -21.98 CAKI-1 71.91 MDA-MB-435 -17.38 HCT-15 32.2
RPMI-8226 -44.19 RXF-393 105.66 SK-MEL-2 41.67 HT29 66.64
SR 28.61 SN12C 63.5 SK-MEL-28 21.39 KM12 -45.47
   TK-10 14.99 SK-MEL-5 -73.95 SW-620 38.13
   UO-31 18.75 UACC-257 -39.68   
     UACC-62 -27.18   
NSC-Lung Cancer CNS Cancer Ovarian Cancer Breast Cancer
A549/ATCC 4.66 SF-268 43.3 IGROV1 28.24 MCF7 5.74
EKVX 66.17 SF-295 43.01 OVCAR-3 14 MDA-MB-231 81.66
HOP-62 0.11 SF-539 77.23 OVCAR-4 1.21 HS-578T 51.84
NCI-H23 -21.22 SNB-19 72.87 OVCAR-5 103.07 BT-549 24.27
NCI-H322M 69.89 SNB-75 81.1 OVCAR-8 -13.39 T-47D -27.58
NCI-H460 25.82 U251 38.81 NCI/ADR-RES -5.97 MDA-MB-468 9.61
NCI-H522 2.5    SK-OV-3 98.1   
Prostate Cancer       
PC-3 0.46      
DU-145 51.79       
  1. NOTE: The numbers reported are from a single dose (10 μM) study and are displayed as growth relative to the no-drug control after 24 hours. Values between 0 and less than 100 indicate growth inhibition whereas values less than 0 (negative values) indicate cytotoxicity.